CoachCare CEO Testifies Before U.S. House Ways and Means Subcommittee on the Future of Remote Patient Monitoring
'This hearing reflects the growing recognition that RPM is not just a promising innovation—it's essential infrastructure for modern healthcare.'— Andrew Zengilowski, CEO and Co-Founder
WASHINGTON, DC, UNITED STATES, June 30, 2025 / EINPresswire.com / -- CoachCare, a leading provider of remote care technology and services, today announced that its CEO and Co-Founder, Andrew Zengilowski, testified before the U.S. House of Representatives Committee on Ways and Means, Subcommittee on Health, during a hearing titled 'Health at Your Fingertips: Harnessing the Power of Digital Health Data.'
As a founding member of the Remote Monitoring Leadership Council, Zengilowski shared CoachCare's frontline experience delivering high-touch, high-tech care to more than 500,000 patients—many in rural and underserved communities—and outlined specific policy recommendations to modernize Medicare reimbursement for Remote Patient Monitoring (RPM).
'This hearing reflects the growing recognition that RPM is not just a promising innovation—it's essential infrastructure for modern healthcare,' said Zengilowski. 'We're proud to advocate for sustainable, data-driven care models that improve outcomes, reduce costs, and expand access for all patients, regardless of geography.'
Championing the Power of Digital Health Data
In his testimony, Zengilowski described how CoachCare combines real-time physiologic data with clinical oversight to shift care from episodic to continuous—preventing unnecessary ER visits and enabling patients to better manage chronic conditions from home. He emphasized that RPM empowers patients with visibility into their own health data while enabling providers to act on early warning signs.
'Remote monitoring turns data into action. When we detect a patient's blood pressure spike, we can intervene immediately—not days or weeks later,' said Zengilowski. 'That's the future of healthcare: proactive, personalized, and data-enabled.'
A Call for Sustainable Reimbursement
Zengilowski also called on Congress to update RPM reimbursement to reflect the full cost and complexity of delivering care today. He cited rising costs for connected devices, information security, and patient engagement—particularly in rural areas where broadband and staffing challenges persist.
'RPM today requires advanced infrastructure and clinical sophistication. We urge lawmakers to align reimbursement with this reality, ensuring continued access for patients and sustainability for the providers who serve them,' Zengilowski said.
His recommendations included:
--Adjusting Medicare reimbursement to reflect the cost of software, cellular connectivity, and multi-device care plans.
--Eliminating geographic payment disparities that disproportionately affect rural and underserved communities.
--Supporting innovation in AI and predictive analytics to further drive value and outcomes.
Building on Momentum
CoachCare's testimony comes on the heels of two major announcements: its acquisition of MD Revolution, a leader in chronic care management and RPM, and its role as a founding member of the Remote Monitoring Leadership Council—solidifying its position at the forefront of remote care innovation and advocacy.
'As we continue to grow, we're also helping shape the policies that determine the future of care,' added Zengilowski. 'We're honored to bring our voice—and the voices of the providers and patients we serve—to Congress.'
To read Zengilowski's written testimony, visit: https://lnkd.in/gC_wUy2Q
To watch the full hearing, visit: https://lnkd.in/eKjwBetn
About CoachCare
Founded in 2014, CoachCare powers remote care for provider organizations, enabling successful programs in RPM, CCM, PCM RTM, BHI, INR, APCM and more. CoachCare's digital platform includes proprietary software and devices, remote care management services, and robust analytics—helping clients achieve clinical outcomes and financial ROI at scale. Backed by over $100 million in funding and nine strategic acquisitions, CoachCare is one of the most established and fastest-growing companies in remote care.
www.coachcare.com
CoachCare Marketing Department
CoachCare
email us here
Visit us on social media:
X
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
iCRYO's CEO and CAO to Join Vitality Business Summit 2025 as Featured Speakers
DALLAS, Aug. 6, 2025 /PRNewswire/ -- iCRYO, a leading health, wellness, and longevity franchise, is excited to announce that its CEO and Co-Founder, Kyle Jones, and Chief Administrative Officer (CAO), Scott Briner, will be featured speakers at the Vitality Business Summit 2025. The summit, scheduled for October 3-5, 2025, at the Hilton DFW Lakes Executive Conference Center in Dallas, Texas, is organized and hosted by brothers Chris and Brad Himel of Himel Health, longtime consultants for health and wellness clinics. Leveraging their network, they are bringing together brand entrepreneurs, clinic owners, and other health enthusiasts to shape the future of health and wellness. Emphasizing practical solutions over passing trends, The Vitality Business Summit promises to equip attendees with the tools to build scalable, purpose-driven businesses. Kyle W. Jones, as a pioneer in cryotherapy and holistic wellness going back to 2015, will join a host of other accomplished leaders in the industry, including acclaimed speaker and author Tim Storey, motivational speaker Jenn Drummond, BrainTap founder Dr. Patrick Porter, business coach Raquel Diehm, and OxyHealth CEO Dr. Mayur Patel, to name a few. "I'm thrilled to speak at the Vitality Business Summit and share the strategies that have fueled iCRYO's growth while keeping wellness accessible," said Jones. "At the same time, this event is a catalyst for change, with innovation and adoption moving ever faster in this space. This summit offers us a chance to keep our finger on the pulse and connect with other professionals building businesses that will make a lasting impact." iCRYO's CAO and former hospital CEO Scott Briner echoed Jones' thoughts, adding, "I'm honored to join Kyle as a speaker and represent iCRYO at the Vitality Business Summit this fall. We've developed what we believe is the new industry-standard for medical care in a retail environment, and we're proud to share it with the world any chance we get. However, we're always looking to learn, grow, and improve iCRYO's service and offerings, and this event gives us that chance." The summit caters to a diverse audience, from solo practitioners to multi-unit clinic owners, offering unparalleled opportunities to learn sales and marketing frameworks used by successful clinics, network with world-class experts, explore dozens of vendors showcasing the latest in wellness modalities and therapies, develop a tailored growth plan, and create lasting partnerships. Early Bird pricing offers up to 50% off General Admission and 33% off VIP tickets, which include a VIP Lunch with speakers on Sunday. Attendees are encouraged to secure their spots now as both General Admission and VIP tickets are going fast with these early bird offers. Event Details: Date: October 3-5, 2025 Location: Hilton DFW Lakes Executive Conference Center, Dallas, Texas Tickets: Available at About iCRYO Founded in 2015, iCRYO's mission is to elevate the quality of life of its team members, guests, and franchisees by providing affordable, professional, and convenient personal health services while raising the standard as a global wellness brand. To learn more about its services, locations, and franchise opportunities, visit iCRYO Media Contact Robbie JenkinsDirector of View original content to download multimedia: SOURCE iCRYO Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Washington Post
11 minutes ago
- Washington Post
RFK Jr.'s slander of mRNA technology will harm Americans
Robert F. Kennedy Jr.'s decision to cancel almost $500 million in contracts for projects to develop vaccines using mRNA technology underscores perhaps the greatest harm that he might inflict on the nation with his anti-vaccine ideology. The disparagement of existing immunizations by the health and human services secretary is dangerous on its own, in that it might persuade people to forego recommended shots and reduce herd immunity against diseases. But potentially even worse are the impacts that will be harder to see: the diseases that public health officials won't be able to fight because of the lifesaving innovations he is cutting short. Kennedy's resistance against mRNA vaccines is without evidence. In fact, the technology — which instructs the body's cells to produce a harmless bit of virus that is then used to train the immune system, as opposed to using weakened or dead versions of a virus — delivered arguably the most important achievement of President Donald Trump's first term: the production of effective vaccines against the novel coronavirus within the span of a few months. Such speed was practically unheard-of in biomedical research. Thanks to the urgency created by Operation Warp Speed, the federal government was able to mount an impressive vaccination rollout that boosted the population's immunity to the coronavirus just when it was needed. As with any medical treatment, these vaccines were not perfect. In very rare instances among adolescents, they resulted in a serious side effect known as myocarditis, or inflammation of the heart muscle. Their effectiveness also waned over time as the coronavirus mutated, as is the case with vaccines for other respiratory diseases. But there can be no doubt: These vaccines saved millions of lives. Kennedy absurdly claimed in a video statement that 'mRNA vaccines don't perform well against viruses that infect the upper respiratory tract.' He further claimed that a single mutation in a virus can render vaccines 'ineffective.' He even went so far as to argue that this effect 'encourages' mutations and could 'prolong' a pandemic. This is just plain wrong, as the covid pandemic demonstrated. The effectiveness of mRNA coronavirus vaccines might have diminished over time, but they continued to protect people against severe illness over the course of multiple strains. In fact, the Centers for Disease Control and Prevention continued to recommend the shots for vulnerable populations for that reason, and manufacturers updated boosters to combat new strains. Giving up on this game-changing technology will slow down scientific innovation, leaving Americans more vulnerable to diseases. Kennedy just canceled or altered 22 mRNA projects that were supported by the Biomedical Advanced Research and Development Authority. On the chopping block are vaccine developments for several respiratory illnesses. That includes a project to defend the country against the H5N1 bird flu virus, which scientists warn could spiral into a deadly pandemic if someone contracts it while also infected with the seasonal flu virus. And that's just the beginning. Researchers are eager to deploy mRNA technology against a slew of other hard-to-tackle pathogens, from hepatitis C to HIV to malaria. There are even efforts to use this approach to activate the immune system to attack cancer cells and to treat other genetic diseases. Some scientists have suggested this research could also be essential for national security, as it might help defend against attacks from biological weapons. Calling Kennedy's latest actions shortsighted understates the gravity of his slander. Americans will bear the cost of his rejection of science.
Forbes
11 minutes ago
- Forbes
USAID And PEPFAR Cuts Could Lead To Massive Loss Of Life Overseas
A Lancet paper published in July evaluates data to illustrate the importance of roughly two decades of American humanitarian aid offered through the United States Agency for International Development and the President's Emergency Plan for AIDS Relief. The piece subsequently projects what the future could look like in light of the steep cuts imposed by President Trump to USAID and PEPFAR. Authors estimate that USAID-funded programs have helped prevent more than 91 million deaths globally in the past 20 years, including 30 million fatalities among children. Projections suggest that ongoing deep funding cuts—combined with the dismantling of the agency—could result in more than 14 million additional deaths by 2030. On inauguration day, President Trump ordered a sweeping 90-day spending freeze on virtually all U.S. foreign aid, including many forms of health and food assistance. An independent agency, USAID, was largely gutted. The USAID undertakes a wide range of activities, which include among other things food aid and distribution (often in conflict zones), clean water provision, maternal and infant health support, mass administration of rehydration salts for children suffering from diarrhea, malaria prevention and treatments and polio vaccinations in countries where the disease is still endemic. The agency was established under President John F. Kennedy in the early 1960s to administer humanitarian aid programs around the world. Congress appropriates funds for USAID's operations. The agency employed roughly 10,000 people, two-thirds of whom worked overseas. In fiscal year 2024, the agency received more than $44 billion in federal funding. Most of that money was spent in Asia, sub-Saharan Africa and Europe (primarily on humanitarian efforts in Ukraine). While a considerable sum, it merely accounts for 0.4% of the entire federal budget. The Trump administration has slashed 86% of USAID funding. Only a small fraction of aid programs remains in place. The employee head count is now under 500. As carried out by successive administrations since Bush, including the first Trump administration, PEPFAR represented the largest commitment in history by any nation to address a single disease, HIV/AIDS. But gradually the second Trump administration is unraveling this initiative, too. KFF reported that while PEPFAR received a limited waiver on Feb. 1, allowing it to continue certain 'life-saving HIV services,' the waiver doesn't include essential pre-exposure prophylaxis for anyone other than pregnant and breastfeeding women. The State Department has sought $2.9 billion in funding to continue HIV-AIDS programs in the next fiscal year—considerably lower than PEPFAR's current budget of $4.1 billion. Moreover, USAID was the main agency working on behalf of PEPFAR. Without USAID and its staff, PEPFAR's implementation capacity has been seriously affected. Going forward, the Trump administration intends to transform PEPFAR from an aid program to one that is aligned with its 'America First' priorities. The plan, as described by the New York Times, outlines the administration's intentions to 'transition' countries off of PEPFAR, in some cases within two years. The program would in essence no longer be involved in aid and saving lives overseas. Rather, it would focus on detecting outbreaks that could threaten the U.S. and at the same time create new markets for American drugs and technologies. On the ground, journalists are painting a grim picture of the implications of the drastic curtailment in U.S. aid. A story in America Magazine, for example, describes in detail the local impact in Eswatini, a country in Southern Africa, of the gutting of USAID and reductions in PEPFAR. Cuts have severely limited access to HIV treatments and testing in clinics. During the height of the HIV/AIDS pandemic, the population of Eswatini plummeted, and life expectancy dropped from 61 in 1988 to 44 by 2003. It reverted to 61 in 2023, thanks in large part to USAID and PEPFAR. But now the gains in health outcomes are in jeopardy. The ramifications of a greatly diminished U.S. presence in health aid, international development and disaster assistance could be profound, specifically around the global humanitarian programs which rely on USAID. In terms of international assistance, the U.S. was by far the world's largest donor. The U.S. spent $68 billion on international aid in 2023. And the Trump administration's actions are also affecting what is termed the President's Malaria Initiative, an organization also founded by former President Bush. Through the work of this entity, the U.S. had become the global leader in donating to anti-malaria programs and research. According to the New York Times, one of Trump's executive orders has led to two-thirds of the staff being let go from the Malaria Initiative. And by pulling out of the World Health Organization, Trump further diminishes the critical role the U.S. plays in combating neglected tropical diseases, such as leishmaniasis, river blindness, Dengue fever and trachoma. These preventable and mostly treatable infectious diseases affect millions of people in tropical regions of the world, causing severe health problems, including anemia, blindness, chronic pain, infertility and bodily disfigurement. Historically, despite the large burden imposed by neglected tropical diseases on many people, they've received a relatively small portion of resources for drug development and treatment distribution. U.S. aid agencies had been filling some of the void. Until now.
